Asset Dedication LLC’s Beam Therapeutics BEAM Stock Holding History

Asset Dedication LLC’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-68	Closed	-$1.62K	–	1247
2026 Q1	$1.62K	Hold	68	–	–	﹤0.01%	984
2025 Q4	$1.89K	Hold	68	–	–	﹤0.01%	1010
2025 Q3	$1.65K	Hold	68	–	–	﹤0.01%	1028
2025 Q2	$1.16K	Sell	68 -200	-75%	-$3.48K	﹤0.01%	1075
2025 Q1	$5.24K	Hold	268	–	–	﹤0.01%	851
2024 Q4	$6.65K	Hold	268	–	–	﹤0.01%	818
2024 Q3	$6.57K	Hold	268	–	–	﹤0.01%	860
2024 Q2	$6.28K	Hold	268	–	–	﹤0.01%	886
2024 Q1	$9K	Buy	268 +200	+294%	+$6.23K	﹤0.01%	695
2023 Q4	$2K	Sell	68 -200	-75%	-$4.97K	﹤0.01%	888
2023 Q3	$7K	Hold	268	–	–	﹤0.01%	725
2023 Q2	$8K	Hold	268	–	–	﹤0.01%	691
2023 Q1	$8K	Hold	268	–	–	﹤0.01%	684
2022 Q4	$11K	Hold	268	–	–	﹤0.01%	642
2022 Q3	$13K	Hold	268	–	–	﹤0.01%	582
2022 Q2	$11K	Hold	268	–	–	﹤0.01%	335
2022 Q1	$15K	Buy	268 +68	+34%	+$4.46K	﹤0.01%	599
2021 Q4	$16K	Hold	200	–	–	﹤0.01%	578
2021 Q3	$17K	Buy	+200	New	+$20.1K	﹤0.01%	591

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Asset Dedication LLC's BEAM Position: Q2 2026 in Review

Asset Dedication LLC sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 68 shares — an estimated $1.62K sold.

Asset Dedication LLC first reported a position in BEAM in Q3 2021 and held it in 19 quarters. The position peaked at $17K in Q3 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Asset Dedication LLC reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
Asset Dedication LLC sold 68 Beam Therapeutics shares in Q2 2026, an estimated $1.62K.
Asset Dedication LLC first reported a position in Beam Therapeutics in Q3 2021 and held it in 19 quarters.
Asset Dedication LLC's Beam Therapeutics position peaked at $17K in Q3 2021.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Asset Dedication LLC's 13F filing for Q2 2026, filed 30 Jul 2026.